ANX1502 proof-of-concept trial to wrap up next year, Annexon says
A proof-of-concept study designed to test a new tablet formulation of the experimental therapy ANX1502 in people with cold agglutinin disease (CAD) is continuing dosing to provide further insights into the therapy’s pharmacological profile and its impact on disease biomarkers. Data so far have been promising, showing that blood…
